SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Caplin Point Laboratories gains on reporting 23% rise in Q1 consolidated net profit

08 Aug 2025 Evaluate

Caplin Point Laboratories is currently trading at Rs 2070.85, up by 13.40 points or 0.65% from its previous closing of Rs 2057.45 on the BSE.

The scrip opened at Rs 2056.50 and has touched a high and low of Rs 2075.00 and Rs 2007.05 respectively. So far 6215 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 2 has touched a 52-week high of Rs 2636.00 on 27-Dec-2024 and a 52-week low of Rs 1451.60 on 09-Aug-2024.

Last one week high and low of the scrip stood at Rs 2081.15 and Rs 1886.55 respectively. The current market cap of the company is Rs 15635.23 crore.

The promoters holding in the company stood at 70.56%, while Institutions and Non-Institutions held 8.39% and 21.05% respectively.

Caplin Point Laboratories has reported 18.40% rise in its net profit at Rs 85.89 crore for the quarter ended June 30, 2025 as compared to Rs 72.54 crore for the same quarter in the previous year. The total income of the company increased by 3.60% at Rs 214.60 crore for Q1FY26 as compared to Rs 207.14 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 23.26% rise in its net profit at Rs 152.80 crore for Q1FY26 as compared to Rs 123.97 crore for the same quarter in the previous year. The total income of the company increased by 11.69% at Rs 533.36 crore for Q1FY26 as compared to Rs 477.52 crore for the corresponding quarter previous year.

Caplin Point Lab Share Price

1772.50 6.05 (0.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×